EX-99.1 2 a16-20581_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

HCP Announces Results for Quarter Ended September 30, 2016

and Completes the QCP Spin Transaction

 

THIRD QUARTER 2016 AND RECENT HIGHLIGHTS

 

--    EPS and FFO per share were $0.32 and $0.65, respectively; FFO as adjusted was $0.72 per share

 

--    Completed spin-off of Quality Care Properties, Inc. (“QCP”) (NYSE:QCP) on October 31, 2016; see separate press release dated October 31, 2016

 

--    Entered into definitive agreements to sell 64 communities triple-net leased to Brookdale Senior Living, Inc. (“Brookdale”) for $1.125 billion and announced other planned transactions, resulting in reduced tenant concentration and improved lease coverage; see separate press release dated November 1, 2016

 

--    Anticipate using proceeds from QCP financing and Brookdale asset sales to deleverage

 

--    Achieved year-over-year three-month SPP Cash NOI and SPP NOI growth of 3.1% and 1.6%, respectively, excluding QCP, led by strong life science and senior housing operating portfolio (“SHOP”) performance

 

--    Completed $254 million of acquisitions and announced $204 million of other dispositions

 

--    Commencing $211 million development of Phase III of The Cove life science project, consisting of two Class A buildings representing up to 336,000 sq. ft.; see separate press release dated November 1, 2016

 

--    Executed 991,000 sq. ft. of leasing in our life science and medical office portfolios, bringing Phase I of The Cove to 73% leased and Phase II to 50% pre-leased

 

UPDATED 2016 GUIDANCE

 

--    Full year 2016 guidance reflects the QCP spin-off completed on October 31, 2016, but does not include the impact of unannounced future transactions: EPS of $1.49 – $1.55, FFO per share of $2.35 – $2.41 and FFO as adjusted per share of $2.69 – $2.75

 

--    Excluding QCP, full year 2016 guidance for SPP Cash NOI growth of 2.75% – 3.75% and SPP NOI growth of 1.7% – 2.7%, led by SHOP and life science

 

FULL YEAR 2017 OUTLOOK

 

--    2017 outlook does not include the impact from unannounced future transactions other than capital recycling activities: EPS of $1.07 – $1.13, FFO per share of $1.88 – $1.94 and FFO as adjusted per share of $1.89 – $1.95

 

--    2017 outlook for SPP Cash NOI growth of 2.5% – 3.5% and SPP NOI growth of 1.5% – 2.5%

 

IRVINE, CA, November 1, 2016 /PRNewswire/ – HCP (NYSE:HCP) announced results for quarter ended September 30, 2016.

 

 

 

Three Months Ended
September 30, 2016

 

Three Months Ended
September 30, 2015

 

Per Share

 

(in thousands, except per share amounts)

 

Amount

 

Per Share

 

Amount

 

Per Share

 

Change

 

Net income

 

 $

150,924

 

 $

0.32

 

 $

115,046

 

 $

0.25

 

 $

0.07

 

FFO

 

 $

304,387

 

 $

0.65

 

 $

263,370

 

 $

0.57

 

 $

0.08

 

Other impairments(1)

 

 

 

96,856

 

0.21

 

(0.21

)

Transaction-related items(2)

 

17,568

 

0.04

 

1,538

 

 

0.04

 

Severance-related charges(3)

 

14,464

 

0.03

 

 

 

0.03

 

Foreign currency remeasurement losses

 

94

 

 

4,036

 

0.01

 

(0.01

)

FFO as adjusted

 

 $

336,513

 

 $

0.72

 

 $

365,800

 

 $

0.79

 

 $

(0.07

)

FAD

 

 $

317,540

 

 

 

 $

309,946

 

 

 

 

 

 

 

 

(1)   For the quarter ended September 30, 2015, other impairments reflect $70 million related to our Four Seasons Health Care senior notes (“Four Seasons Notes”) and $27 million related to our 9% equity investment in HCR ManorCare, Inc. (“HCRMC”).

(2)   Transaction-related items for the quarter ended September 30, 2016 primarily consist of costs incurred for the spin-off of QCP.

(3)   Severance-related charges for the quarter ended September 30, 2016 primarily relate to the previously announced departure of our former President and CEO.

 

Page 1 of 16



 

During the third quarter 2016, operating results, excluding FAD, reflect placing our HCRMC investments on cash basis effective January 1, 2016. The prior year comparable period included non-cash HCRMC income of $0.08 per share.  Results for the third quarter 2016 included the impact of an interest income benefit of $0.01 per share from the payoff of a senior housing development loan, representing our participation in the appreciation of the real estate.

 

FFO, FFO as adjusted, FAD, SPP Cash NOI excluding QCP and SPP NOI excluding QCP are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance of real estate investment trusts. See the “Funds From Operations”, “Funds Available for Distribution” and “Net Operating Income and Same Property Performance” sections of this release for additional information regarding these non-GAAP financial measures.

 

STRATEGIC BROOKDALE TRANSACTIONS AND OTHER DISPOSITIONS

 

BROOKDALE ASSET SALES & TRANSITIONS

 

Today we announced that we entered into definitive agreements to sell 64 communities triple-net leased to Brookdale for $1.125 billion to affiliates of Blackstone Real Estate Partners VIII L. P. The transaction is expected to close in the first quarter of 2017, and we intend to use the proceeds to pay down debt. In addition, we have agreed with Brookdale to sell or transition 25 triple-net leased assets within the next 12 months and transfer eight expiring Brookdale leases to RIDEA structures, including the transition of four assets to a new regional operator during the fourth quarter of 2016. Combined, these transactions will advance our strategic initiatives to reduce Brookdale concentration while improving lease coverage, diversifying our operator relationships and strengthening our balance sheet and credit profile. A copy of the corresponding press release with additional details is available on the Investor Relations section of our website at http://ir.hcpi.com.

 

OTHER DISPOSITIONS & TRANSITIONS

 

During the third quarter and through October 31, 2016, we announced $204 million of additional dispositions. Significant transactions include:

 

·     In October, we sold seven of ten properties subject to a master lease to the current operator for an aggregate purchase price of $88 million. As part of this transaction, we provided a $10 million mezzanine loan with a 5-year term at a 9% interest rate. Concurrently, we modified the in-place master lease to transition the operations of the remaining three properties to a new regional operator.

 

·     Executed definitive agreements to sell four life science facilities in Salt Lake City, UT encompassing 324,000 sq. ft. for $76 million to the current tenant. The transaction is expected to close in the first quarter of 2017.

 

For full year 2016, we expect to generate approximately $1.3 billion of proceeds from dispositions, inclusive of proceeds from the previously announced RIDEA II transaction.

 

INVESTMENT TRANSACTIONS

 

During the third quarter and through October 31, 2016, we completed $254 million of acquisitions, bringing our year-to-date total investments to $711 million. Significant transactions included:

 

·     We completed the previously announced acquisition of seven private pay senior housing communities for $186 million, welcoming a new operating partner to our SHOP platform, Senior Lifestyle Corporation.

 

·     As announced last quarter, we acquired two Class A life science buildings totaling 137,000 sq. ft. and a four-acre parcel of land in San Diego, CA for $49 million, growing our life science footprint in a core market.

 

BALANCE SHEET AND FINANCING ACTIVITIES

 

THIRD QUARTER 2016 AND RECENT HIGHLIGHTS

 

In September, we repaid $400 million of maturing senior notes with an interest rate of 6.3%. We ended the third quarter with $1.4 billion drawn on our revolving line of credit facility and $0.6 billion of remaining capacity.

 

In October, S&P reaffirmed our BBB credit ratings, while Fitch reaffirmed our BBB credit ratings and improved our outlook to stable.

 

Page 2 of 16



 

LIFE SCIENCE AND MEDICAL OFFICE LEASING

 

During the third quarter, we completed 991,000 sq. ft. of leasing in our life science and medical office portfolios, consisting of 429,000 sq. ft. of new leases and 562,000 sq. ft. of renewals. Significant leasing transactions were primarily in our life science portfolio, including:

 

·     10-year lease with AstraZeneca Pharmaceuticals LP, a biopharmaceutical company, for 116,000 sq. ft. at The Cove Phase II, bringing this phase to 50% pre-leased

 

·     Two 8-year leases totaling 65,000 sq. ft. at The Cove Phase I, bringing this phase to 73% leased

 

·     8.5-year lease for 77,000 sq. ft. in San Diego, CA

 

In response to the leasing success at The Cove and continued strong demand from life science users in South San Francisco, we are commencing the $211 million development of Phase III, which adds two Class A buildings representing up to 336,000 sq. ft., expected to be delivered by the fourth quarter of 2018. A copy of the press release is available on the Investor Relations section of our website at http://ir.hcpi.com.

 

Visit our website for additional information, including a link to view our development progress at The Cove, at www.hcpi.com/portfolio-diversification/life-science.

 

HCR MANORCARE (“HCRMC”) UPDATE

 

SPIN TRANSACTION

 

On October 31, 2016, we completed the spin-off of QCP into an independent publicly-traded REIT. A copy of the press release and our HCP 3.0 Post-Spin Outlook Presentation are available on the Investor Relations section of our website at http://ir.hcpi.com.

 

HCRMC THIRD QUARTER OPERATING PERFORMANCE

 

For the third quarter 2016, HCRMC reported normalized EBITDAR of $119 million, bringing the year-to-date total to $382 million. HCRMC’s normalized fixed charge coverage ratio for the trailing twelve months ended September 30, 2016 was 1.02x. EBITDAR losses from the 33 non-strategic assets that have sold to date, including transaction costs, totaled $9 million for the reported twelve-month period. In addition, EBITDAR losses for the remaining 17 non-strategic assets were $10 million for the same period. Upon excluding EBITDAR losses and the rent associated with the 33 assets sold to date, the trailing twelve month normalized fixed charge coverage would have been 1.04x. HCRMC ended the third quarter with $164 million of cash and cash equivalents.

 

DIVIDEND

 

This morning we announced that our Board of Directors declared a quarterly cash dividend of $0.37 per common share. The dividend will be paid on November 25, 2016 to stockholders of record as of the close of business on November 10, 2016. A copy of the corresponding press release is available on the Investor Relations section of our website at http://ir.hcpi.com.

 

SUSTAINABILITY

 

In September 2016, HCP was named to the Dow Jones Sustainability North America Index for the fourth consecutive year and the Dow Jones Sustainability World Index for the second consecutive year. In addition, we achieved the “Green Star” designation from the Global Real Estate Sustainability Benchmark (GRESB) for the fifth year in a row, representing the highest quadrant of achievement in GRESB’s annual sustainability survey. Information about HCP’s sustainability efforts can be found on our website at www.hcpi.com/sustainable-growth.

 

Page 3 of 16



 

OUTLOOK

 

2016 GUIDANCE

 

Full year 2016 guidance reflects the QCP spin-off completed on October 31, 2016 and the impact of $1.3 billion of dispositions expected in 2016, inclusive of the RIDEA II transaction. Our guidance does not include the impact of unannounced future transactions. For full year 2016, we expect: EPS to range between $1.49 and $1.55; FFO per share to range between $2.35 and $2.41; and FFO as adjusted per share to range between $2.69 and $2.75. Excluding QCP, we expect 2016 SPP Cash NOI to range between 2.75% and 3.75%, and SPP NOI to range between 1.7% and 2.7%. Refer to the “Projected Future Operations” and “Projected SPP Cash NOI and SPP NOI” sections of this release for additional information regarding these estimates.

 

 

 

Projected Full Year 2016
SPP Cash NOI
(1)

 

Projected Full Year 2016
SPP NOI
(1)

 

 

 

Low

 

High

 

Low

 

High

 

Senior housing triple-net

 

0.5%

 

1.5%

 

0.3%

 

1.3%

 

Senior housing operating portfolio (SHOP)

 

3.75%

 

4.75%

 

3.75%

 

4.75%

 

Life science

 

7.25%

 

8.25%

 

3.7%

 

4.7%

 

Medical office

 

2.3%

 

3.3%

 

1.3%

 

2.3%

 

Other(2)

 

0.75%

 

1.75%

 

1.4%

 

2.4%

 

SPP growth

 

2.75%

 

3.75%

 

1.7%

 

2.7%

 

 


(1)          SPP Cash NOI and SPP NOI exclude assets transferred to QCP and include the impact from our pro rata share of unconsolidated joint ventures. Applying our current methodology of including our pro rata share of unconsolidated joint ventures, the August 9, 2016 mid-point 2016 full year projected SPP Cash NOI for total HCP, excluding QCP, would be 2.8% and for our SHOP platform would be 4.1%.

(2)          Other primarily includes our hospitals, U.K. real estate and all debt investments. See our Supplemental Report for additional details.

 

2017 OUTLOOK

 

Full year 2017 outlook is preliminary and subject to change. It does not include the impact from unannounced future transactions other than capital recycling activities, but does reflect the impact of the Brookdale transactions announced today and other dispositions expected in 2017. For full year 2017, we expect: EPS to range between $1.07 and $1.13; FFO per share to range between $1.88 and $1.94; and FFO as adjusted per share to range between $1.89 and $1.95. In addition, we expect 2017 SPP Cash NOI to range between 2.5% and 3.5%, and SPP NOI to range between 1.5% and 2.5%. Refer to the “Projected Future Operations” and “Projected SPP Cash NOI and SPP NOI” sections of this release for additional information regarding these estimates.

 

 

 

Projected Full Year 2017
SPP Cash NOI

 

Projected Full Year 2017
SPP NOI

 

 

 

Low

 

High

 

Low

 

High

 

Senior housing triple-net

 

3.25%

 

4.25%

 

1.2%

 

2.2%

 

SHOP

 

4.0%

 

5.0%

 

4.0%

 

5.0%

 

Life science

 

1.7%

 

2.7%

 

(0.9)%

 

0.1%

 

Medical office

 

2.0%

 

3.0%

 

2.2%

 

3.2%

 

Other

 

0.75%

 

1.75%

 

1.7%

 

2.7%

 

SPP growth

 

2.5%

 

3.5%

 

1.5%

 

2.5%

 

 

Page 4 of 16



 

COMPANY INFORMATION

 

HCP has scheduled a conference call and webcast for Tuesday, November 1, 2016 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) to present its performance and operating results for the quarter ended September 30, 2016. The conference call is accessible by dialing (888) 317-6003 (U.S.) or (412) 317-6061 (International). The conference ID number is 8126374. You may also access the conference call via webcast at www.hcpi.com. This link can be found in the “News and Events” section, which is under “Investor Relations”. Through November 16, 2016, an archive of the webcast will be available on our website, and a telephonic replay can be accessed by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and entering conference ID number 10094605. Our HCP 3.0 Post-Spin Outlook Presentation and supplemental information package for the current period are available with this earnings release on our website in the “Financial Information” section under “Investor Relations”.

 

ABOUT HCP

 

HCP, Inc. is a fully integrated real estate investment trust (REIT) that invests primarily in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio diversified across multiple sectors, led by senior housing, life science and medical office. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index. For more information regarding HCP, visit www.hcpi.com.

 

###

 

Page 5 of 16



 

FORWARD-LOOKING STATEMENTS

 

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this release which are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, among other things, (i) all statements under the heading “Outlook,” including without limitation with respect to expected EPS, FFO per share, FFO as adjusted per share, SPP Cash NOI and SPP NOI projections, and other financial projections and assumptions, including those in the “Projected Future Operations,” “Other Supplemental Information” and “Projected SPP NOI and SPP Cash NOI” sections of this release, as well as comparable statements included in other sections of this release; (ii) statements regarding the payment of the quarterly cash dividend; and (iii) statements regarding timing, outcomes and other details relating to the pending or contemplated acquisitions, dispositions, developments, joint venture transactions, capital recycling and financing activities, and other transactions discussed in this release, including without limitation those described under the heading “Strategic Brookdale Transactions and Other Dispositions.” These statements are made as of the date hereof, are not guarantees of future performance and are subject to known and unknown risks, uncertainties, assumptions and other factors—many of which are out of HCP’s and its management’s control and difficult to forecast—that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our reliance on a concentration of a small number of tenants and operators for a significant portion of our revenues, with our concentration in Brookdale increasing as a result of the consummation of the spin-off of QCP on October 31, 2016; the financial condition of our existing and future tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings, which results in uncertainties regarding our ability to continue to realize the full benefit of such tenants’ and operators’ leases and borrowers’ loans; the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations; competition for tenants and operators, including with respect to new leases and mortgages and the renewal or rollover of existing leases; competition for skilled management and other key personnel; availability of suitable properties to acquire at favorable prices and the competition for the acquisition and financing of those properties; our ability to negotiate the same or better terms with new tenants or operators if existing leases are not renewed or we exercise our right to replace an existing tenant or operator upon default; the risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our ability to achieve the benefits of investments, including those investments discussed above, within expected time frames or at all, or within expected cost projections; the potential impact on us and our tenants, operators and borrowers from current and future litigation matters, including the possibility of larger than expected litigation costs, adverse results and related developments; the effect on our tenants and operators of legislation and other legal requirements, including licensure, certification and inspection requirements, and laws addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements; changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of compliance or increase the costs, or otherwise affect the operations, of our tenants and operators; volatility or uncertainty in the capital markets, the availability and cost of capital as impacted by interest rates, changes in our credit ratings, and the value of our common stock, and other conditions that may adversely impact our ability to fund our obligations or consummate transactions, or reduce the earnings from potential transactions; changes in global, national and local economic conditions, and currency exchange rates; changes in the credit ratings on U.S. government debt securities or default or delay in payment by the government of its obligations; our ability to manage our indebtedness level and changes in the terms of such indebtedness; the ability to maintain our qualification as a real estate investment trust; the impact of the spin-off transaction on our business; and other risks and uncertainties described from time to time in HCP’s Securities and Exchange Commission filings. The Company cautions investors not to place undue reliance on any forward-looking statements. HCP assumes no, and hereby disclaims any, obligation to update any of the foregoing or any other forward-looking statements as a result of new information or new or future developments, except as otherwise required by law.

 

CONTACT

 

Thomas M. Herzog

Executive Vice President and Chief Financial Officer

949-407-0400

 

Page 6 of 16



 

HCP, Inc.

 

Consolidated Balance Sheets

 

In thousands, except share and per share data

(Unaudited)

 

 

 

 

September 30,

 

December 31,

 

 

 

2016

 

2015

 

Assets

 

 

 

 

 

Real estate:

 

 

 

 

 

Buildings and improvements

 

 $

12,534,471

 

$

12,198,704

 

Development costs and construction in progress

 

395,349

 

388,576

 

Land

 

1,971,601

 

1,948,757

 

Accumulated depreciation and amortization

 

(2,799,969

)

(2,541,334

)

Net real estate

 

12,101,452

 

11,994,703

 

 

 

 

 

 

 

Net investment in direct financing leases (“DFLs”)

 

5,860,401

 

5,905,009

 

Loans receivable, net

 

682,994

 

768,743

 

Investments in and advances to unconsolidated joint ventures

 

592,097

 

605,244

 

Accounts receivable, net of allowance of $4,704 and $3,261, respectively

 

41,371

 

48,929

 

Cash and cash equivalents

 

132,891

 

346,500

 

Restricted cash

 

71,727

 

60,616

 

Intangible assets, net

 

538,631

 

603,706

 

Real estate and related assets held for sale, net

 

372,968

 

314,126

 

Other assets, net

 

794,013

 

802,273

 

 

 

 

 

 

 

Total assets

 

 $

21,188,545

 

$

21,449,849

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

Bank line of credit

 

 $

1,372,032

 

$

397,432

 

Term loans

 

462,181

 

524,807

 

Senior unsecured notes

 

8,229,731

 

9,120,107

 

Mortgage debt

 

762,715

 

932,212

 

Other debt

 

93,876

 

94,445

 

Intangible liabilities, net

 

46,135

 

56,147

 

Intangible and other liabilities related to assets held for sale, net

 

23,002

 

19,126

 

Accounts payable and accrued liabilities

 

487,033

 

436,239

 

Deferred revenue

 

136,406

 

123,017

 

Total liabilities

 

11,613,111

 

11,703,532

 

 

 

 

 

 

 

Common stock, $1.00 par value: 750,000,000 shares authorized; 467,820,181 and 465,488,492 shares issued and outstanding, respectively

 

467,820

 

465,488

 

Additional paid-in capital

 

11,720,552

 

11,647,039

 

Cumulative dividends in excess of earnings

 

(2,975,096

)

(2,738,414

)

Accumulated other comprehensive loss

 

(30,164

)

(30,470

)

Total stockholders’ equity

 

9,183,112

 

9,343,643

 

 

 

 

 

 

 

Joint venture partners

 

212,807

 

217,066

 

Non-managing member unitholders

 

179,515

 

185,608

 

Total noncontrolling interests

 

392,322

 

402,674

 

 

 

 

 

 

 

Total equity

 

9,575,434

 

9,746,317

 

 

 

 

 

 

 

Total liabilities and equity

 

 $

21,188,545

 

$

21,449,849

 

 

Page 7 of 16



 

HCP, Inc.

 

Consolidated Statements of Operations

 

In thousands, except per share data

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2016

 

2015

 

2016

 

2015

 

 

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

 

 

Rental and related revenues

 

$

297,178

 

$

293,566

 

$

893,448

 

$

845,382

 

Tenant recoveries

 

35,195

 

33,084

 

100,862

 

94,356

 

Resident fees and services

 

170,752

 

155,290

 

500,717

 

367,141

 

Income from direct financing leases

 

130,663

 

155,717

 

390,731

 

478,976

 

Interest income

 

20,482

 

19,842

 

71,298

 

89,049

 

Total revenues

 

654,270

 

657,499

 

1,957,056

 

1,874,904

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Interest expense

 

117,860

 

122,157

 

361,255

 

357,569

 

Depreciation and amortization

 

142,874

 

134,704

 

425,582

 

369,629

 

Operating

 

188,747

 

173,515

 

545,827

 

441,888

 

General and administrative

 

34,787

 

20,534

 

83,079

 

74,152

 

Acquisition and pursuit costs

 

17,568

 

1,553

 

34,570

 

23,350

 

Impairments

 

 

69,622

 

 

592,921

 

Total costs and expenses

 

501,836

 

522,085

 

1,450,313

 

1,859,509

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

(Loss) gain on sales of real estate

 

(9

)

52

 

119,605

 

6,377

 

Other income (expense), net

 

1,454

 

(572

)

5,128

 

13,125

 

Total other income (expense), net

 

1,445

 

(520

)

124,733

 

19,502

 

 

 

 

 

 

 

 

 

 

 

Income before income taxes and equity (loss) income from and impairment of unconsolidated joint ventures

 

153,879

 

134,894

 

631,476

 

34,897

 

Income tax benefit (expense)

 

2,213

 

1,980

 

(48,822

)

6,620

 

Equity (loss) income from unconsolidated joint ventures

 

(2,053

)

8,314

 

(4,028

)

33,916

 

Impairment of investments in unconsolidated joint ventures

 

 

(27,234

)

 

(27,234

)

 

 

 

 

 

 

 

 

 

 

Net income

 

154,039

 

117,954

 

578,626

 

48,199

 

Noncontrolling interests’ share in earnings

 

(2,789

)

(2,592

)

(9,540

)

(8,566

)

 

 

 

 

 

 

 

 

 

 

Net income attributable to HCP, Inc.

 

151,250

 

115,362

 

569,086

 

39,633

 

Participating securities’ share in earnings

 

(326

)

(316

)

(977

)

(1,020

)

 

 

 

 

 

 

 

 

 

 

Net income applicable to common shares

 

$

150,924

 

$

115,046

 

$

568,109

 

$

38,613

 

 

 

 

 

 

 

 

 

 

 

Earnings per common share:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.32

 

$

0.25

 

$

1.22

 

$

0.08

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$

0.32

 

$

0.25

 

$

1.22

 

$

0.08

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to calculate earnings per common share:

 

 

 

 

 

 

 

 

 

Basic

 

467,628

 

463,337

 

466,931

 

462,039

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

467,835

 

463,586

 

467,132

 

462,302

 

 

Page 8 of 16



 

HCP, Inc.

 

Consolidated Statements of Cash Flows

 

In thousands

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2016

 

2015

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

578,626

 

$

48,199

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

425,582

 

369,629

 

Amortization of market lease intangibles, net

 

(1,393

)

(980

)

Amortization of deferred compensation

 

19,307

 

21,068

 

Amortization of deferred financing costs

 

15,598

 

14,950

 

Straight-line rents

 

(14,412

)

(24,817

)

Loan and direct financing lease non-cash interest

 

385

 

(71,243

)

Deferred rental revenues

 

(1,027

)

(1,496

)

Equity loss (income) from unconsolidated joint ventures

 

4,028

 

(33,916

)

Distributions of earnings from unconsolidated joint ventures

 

5,919

 

4,587

 

Lease termination income, net

 

 

(1,103

)

Gain on sales of real estate

 

(119,605

)

(6,377

)

Deferred income tax expense

 

47,195

 

 

Foreign exchange and other gains, net

 

(127

)

(7,103

)

Impairments

 

 

620,155

 

Changes in:

 

 

 

 

 

Accounts receivable, net

 

7,558

 

(10,634

)

Other assets, net

 

(9,674

)

(1,186

)

Accounts payable and accrued liabilities

 

40,672

 

(52,073

)

Net cash provided by operating activities

 

998,632

 

867,660

 

Cash flows from investing activities:

 

 

 

 

 

Acquisitions of real estate

 

(257,242

)

(1,200,661

)

Development of real estate

 

(304,818

)

(190,082

)

Leasing costs and tenant and capital improvements

 

(64,501

)

(52,371

)

Proceeds from sales of real estate, net

 

211,810

 

19,555

 

Contributions to unconsolidated joint ventures

 

(10,169

)

(43,242

)

Distributions in excess of earnings from unconsolidated joint ventures

 

14,458

 

16,086

 

Proceeds from the sales of marketable securities

 

 

782

 

Principal repayments on loans receivable, DFLs and other

 

221,179

 

51,491

 

Investments in loans receivable and other

 

(129,335

)

(283,252

)

Decrease (increase) in restricted cash

 

4,459

 

(3,891

)

Net cash used in investing activities

 

(314,159

)

(1,685,585

)

Cash flows from financing activities:

 

 

 

 

 

Net borrowings under bank line of credit

 

1,157,897

 

282,099

 

Repayments under bank line of credit

 

(135,000

)

(102,063

)

Borrowings under term loan

 

 

333,014

 

Issuance of senior unsecured notes

 

 

1,338,555

 

Repayments of senior unsecured notes

 

(900,000

)

(400,000

)

Repayments of mortgage and other debt

 

(249,540

)

(50,187

)

Deferred financing costs

 

(1,057

)

(14,556

)

Issuance of common stock and exercise of options

 

59,184

 

169,497

 

Repurchase of common stock

 

(8,667

)

(8,006

)

Dividends paid on common stock

 

(806,243

)

(783,578

)

Issuance of noncontrolling interests

 

4,785

 

4,812

 

Distributions to noncontrolling interests

 

(18,687

)

(13,707

)

Net cash (used in) provided by financing activities

 

(897,328

)

755,880

 

Effect of foreign exchange on cash and cash equivalents

 

(754

)

(1,267

)

Net decrease in cash and cash equivalents

 

(213,609

)

(63,312

)

Cash and cash equivalents, beginning of period

 

346,500

 

183,810

 

Cash and cash equivalents, end of period

 

$

132,891

 

$

120,498

 

 

Page 9 of 16



 

HCP, Inc.

 

Funds From Operations(1)

 

In thousands, except per share data

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2016

 

2015

 

2016

 

2015

 

 

 

 

 

 

 

 

 

 

 

Net income applicable to common shares

 

 $

150,924

 

 $

115,046

 

 $

568,109

 

 $

38,613

 

Depreciation and amortization

 

142,874

 

134,704

 

425,582

 

369,629

 

Other depreciation and amortization(2)

 

2,986

 

5,204

 

8,922

 

17,016

 

Loss (gain) on sales of real estate

 

9

 

(52

)

(119,605

)

(6,377

)

Taxes associated with real estate disposition(3)

 

257

 

 

53,434

 

 

Impairment of real estate

 

 

 

 

2,948

 

Equity loss (income) from unconsolidated joint ventures

 

2,053

 

(8,314

)

4,028

 

(33,916

)

FFO from unconsolidated joint ventures

 

10,554

 

20,530

 

32,104

 

69,322

 

Noncontrolling interests’ and participating securities’ share in earnings

 

3,115

 

2,908

 

10,517

 

9,586

 

Noncontrolling interests’ and participating securities’ share in FFO

 

(8,385

)

(6,656

)

(26,227

)

(18,983

)

FFO applicable to common shares

 

 $

304,387

 

 $

263,370

 

 $

956,864

 

 $

447,838

 

Distributions on dilutive convertible units

 

2,376

 

2,365

 

10,622

 

 

Diluted FFO applicable to common shares

 

 $

306,763

 

 $

265,735

 

 $

967,486

 

 $

447,838

 

 

 

 

 

 

 

 

 

 

 

Diluted FFO per common share

 

 $

0.65

 

 $

0.57

 

 $

2.05

 

 $

0.97

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to calculate diluted FFO per share

 

471,994

 

467,772

 

473,011

 

462,302

 

 

 

 

 

 

 

 

 

 

 

Impact of adjustments to FFO:

 

 

 

 

 

 

 

 

 

Other impairments(4)

 

 $

 

 $

96,856

 

 $

 

 $

617,207

 

Transaction-related items

 

17,568

 

1,538

 

34,570

 

28,973

 

Severance-related charges(5)

 

14,464

 

 

14,464

 

6,713

 

Foreign currency remeasurement losses (gains)

 

94

 

4,036

 

268

 

(5,497

)

 

 

 $

32,126

 

 $

102,430

 

 $

49,302

 

 $

647,396

 

 

 

 

 

 

 

 

 

 

 

FFO as adjusted applicable to common shares

 

 $

336,513

 

 $

365,800

 

 $

1,006,166

 

 $

1,095,234

 

Distributions on dilutive convertible units and other

 

3,467

 

3,443

 

10,549

 

10,198

 

Diluted FFO as adjusted applicable to common shares

 

 $

339,980

 

 $

369,243

 

 $

1,016,715

 

 $

1,105,432

 

 

 

 

 

 

 

 

 

 

 

Per common share impact of adjustments on diluted FFO

 

 $

0.07

 

 $

0.22

 

 $

0.10

 

 $

1.39

 

 

 

 

 

 

 

 

 

 

 

Diluted FFO as adjusted per common share

 

 $

0.72

 

 $

0.79

 

 $

2.15

 

 $

2.36

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to calculate diluted FFO as adjusted per share

 

473,692

 

469,590

 

473,011

 

468,320

 

 


(1)          See “Results of Operations-Non-GAAP Financial Measures” and “Non-GAAP Financial Measures Reconciliations” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 for definitions of FFO and FFO as adjusted and an important discussion of their uses and inherent limitations.

 

(2)          Other depreciation and amortization includes DFL depreciation and lease incentive amortization (reduction of straight-line rents) for the consideration given to terminate the 30 purchase options of the 153-property amended lease portfolio in the 2014 Brookdale transaction. Beginning January 2016, we changed our accounting treatment for the HCRMC DFL investments to recognize rental income on a cash basis. As such, we no longer recognize non-cash depreciation related to the HCRMC DFL investments.

 

(3)          For the nine months ended September 30, 2016, net income includes $53 million, of which $49 million relates to the HCRMC real estate portfolio, of income tax expense associated with state built-in gain tax payable upon the disposition of specific real estate assets. See Note 5 to the Consolidated Financial Statements for the quarter ended September 30, 2016 included in our Quarterly Report on Form 10-Q.

 

(4)          For the three months ended September 30, 2015, other impairments include: (i) $70 million related to our Four Seasons Notes and (ii) $27 million related to our equity investment in HCRMC. For the nine months ended September 30, 2015, other impairments include: (i) $478 million related to our DFL investments with HCRMC, (ii) $112 million related to our Four Seasons Notes and (iii) $27 million related to our equity investment in HCRMC.

 

(5)          The severance-related charges for the three and nine months ended September 30, 2016, primarily relate to the departure of our former President and Chief Executive Officer. The severance-related charges for the nine months ended September 30, 2015, relate to the resignation of our former Executive Vice President and Chief Investment Officer.

 

Page 10 of 16



 

HCP, Inc.

 

Funds Available for Distribution(1)

 

In thousands

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2016

 

2015

 

2016

 

2015

 

 

 

 

 

 

 

 

 

 

 

FFO as adjusted applicable to common shares

 

 $

336,513

 

 $

365,800

 

 $

1,006,166

 

 $

1,095,234

 

Amortization of market lease intangibles, net

 

(421

)

(344

)

(1,393

)

(980

)

Amortization of deferred compensation(2)

 

3,389

 

5,344

 

12,894

 

18,174

 

Amortization of deferred financing costs

 

5,037

 

5,224

 

15,598

 

14,950

 

Straight-line rents

 

(3,295

)

(7,069

)

(14,412

)

(24,817

)

DFL non-cash interest(3)

 

637

 

(22,662

)

1,967

 

(64,176

)

Other depreciation and amortization

 

(2,986

)

(5,204

)

(8,921

)

(17,016

)

Deferred revenues – tenant improvement related

 

(459

)

(746

)

(1,451

)

(2,137

)

Deferred revenues – additional rents

 

240

 

254

 

424

 

641

 

Leasing costs and tenant and capital improvements

 

(22,722

)

(23,212

)

(62,774

)

(50,879

)

Lease restructure payments(4)

 

1,868

 

6,067

 

14,480

 

16,368

 

Joint venture adjustments – CCRC entrance fees(5)

 

7,201

 

8,386

 

22,424

 

22,048

 

Joint venture and other FAD adjustments(3)

 

(7,462

)

(21,892

)

(20,565

)

(59,153

)

FAD applicable to common shares

 

 $

317,540

 

 $

309,946

 

 $

964,437

 

 $

948,257

 

Distributions on dilutive convertible units

 

3,513

 

3,547

 

10,622

 

10,683

 

 

 

 

 

 

 

 

 

 

 

Diluted FAD applicable to common shares

 

 $

321,053

 

 $

313,493

 

 $

975,059

 

 $

958,940

 

 


(1)          See “Results of Operations-Non-GAAP Financial Measures” and “Non-GAAP Financial Measures Reconciliations” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 for the definition of FAD and an important discussion of its uses and inherent limitations.

 

(2)          Excludes $6 million primarily related to the acceleration of deferred compensation for restricted stock units and stock options that vested upon the departure of our former President and Chief Executive Officer, which is included in the severance-related charges for the three and nine months ended September 30, 2016. Excludes $3 million related to the acceleration of deferred compensation for restricted stock units and stock options that vested upon the resignation of HCP’s former Executive Vice President and Chief Investment Officer, which is included in the severance-related charges for the nine months ended September 30, 2015.

 

(3)          For the three and nine months ended September 30, 2015, DFL non-cash interest reflects an elimination of $14 million and $44 million, respectively. Our equity investment in HCRMC is accounted for using the equity method, which requires an elimination of DFL income that is proportional to our ownership in HCRMC. Further, our share of earnings from HCRMC (equity income) increases for the corresponding elimination of related lease expense recognized at the HCRMC entity level, which we present as a non-cash joint venture FAD adjustment. Beginning January 2016, equity income is recognized only if cash distributions are received from HCRMC; as a result, we no longer eliminate our proportional ownership share of income from DFLs to equity income (loss) from unconsolidated joint ventures for our equity investment in HCRMC.

 

(4)          Over a period of three years from the closing of a transaction with Brookdale in 2014, we will receive installment payments valued at $55 million for terminating the leases on the HCP owned 49-property portfolio; we include these installment payments in FAD as the payments are collected.

 

(5)          Represents our 49% share of non-refundable entrance fees included in FAD as the fees are collected by our CCRC JV.

 

Page 11 of 16



 

HCP, Inc.

 

Net Operating Income and Same Property Performance(1)

 

Dollars in thousands

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2016

 

2015

 

2016

 

2015

 

Net income

 

 $

154,039

 

 $

117,954

 

 $

578,626

 

 $

48,199

 

Interest income

 

(20,482

)

(19,842

)

(71,298

)

(89,049

)

Interest expense

 

117,860

 

122,157

 

361,255

 

357,569

 

Depreciation and amortization

 

142,874

 

134,704

 

425,582

 

369,629

 

General and administrative

 

34,787

 

20,534

 

83,079

 

74,152

 

Acquisition and pursuit costs

 

17,568

 

1,553

 

34,570

 

23,350

 

Impairment

 

 

69,622

 

 

592,921

 

Loss (gain) on sales of real estate

 

9

 

(52

)

(119,605

)

(6,377

)

Other (income) expense, net

 

(1,454

)

572

 

(5,128

)

(13,125

)

Income tax (benefit) expense(2)

 

(2,213

)

(1,980

)

48,822

 

(6,620

)

Equity loss (income) from unconsolidated joint ventures

 

2,053

 

(8,314

)

4,028

 

(33,916

)

Impairment of investments in unconsolidated joint ventures

 

 

27,234

 

 

27,234

 

HCP’s share of unconsolidated joint ventures revenues

 

53,814

 

48,595

 

160,779

 

141,892

 

HCP’s share of unconsolidated joint ventures operating expenses

 

(43,037

)

(39,820

)

(126,899

)

(114,089

)

NOI

 

 $

455,818

 

 $

472,917

 

 $

1,373,811

 

 $

1,371,770

 

Non-SPP NOI

 

(20,949

)

(23,823

)

(146,575

)

(96,436

)

SPP NOI

 

 $

434,869

 

 $

449,094

 

 $

1,227,236

 

 $

1275,334

 

QCP SPP NOI

 

(123,914

)

(142,967

)

(368,240

)

(436,182

)

SPP NOI, excluding QCP(3)

 

 $

310,955

 

 $

306,127

 

 $

858,996

 

 $

839,152

 

Non-cash adjustment to SPP NOI, excluding QCP

 

(1,344

)

(5,793

)

(8,056

)

(18,383

)

SPP cash (adjusted) NOI, excluding QCP(3)

 

 $

309,611

 

 $

300,334

 

 $

850,940

 

 $

820,769

 

 

 

 

 

 

 

 

 

 

 

NOI % change – SPP, excluding QCP(3)

 

1.6%

 

 

 

2.4%

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash (adjusted) NOI % change – SPP, excluding QCP(3)

 

3.1%

 

 

 

3.7%

 

 

 

 


(1)          See “Results of Operations-Non-GAAP Financial Measures” and “Non-GAAP Financial Measures Reconciliations” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 for definitions of NOI, Cash NOI and SPP and an important discussion of their uses and inherent limitations.

 

(2)          For the nine months ended September 30, 2016, net income includes $53 million, of which $49 million relates to the HCRMC real estate portfolio, of income tax expense associated with state built-in gain tax payable upon the disposition of specific real estate assets. See Note 5 to the Consolidated Financial Statements for the quarter ended September 30, 2016 included in our Quarterly Report on Form 10-Q.

 

(3)          SPP Cash NOI, excluding QCP represents SPP NOI excluding income from DFLs associated with the HCRMC leased properties and rental and related revenues from 28 other healthcare related properties included in spin-off of QCP. SPP Cash NOI, excluding QCP allows management to evaluate the performance of our remaining real estate portfolio following the completion of the spin-off of QCP.

 

Page 12 of 16



 

HCP, Inc.

 

Projected Future Operations(1)

(Unaudited)

 

 

 

Full Year 2016

 

Full Year 2017

 

 

 

Low

 

High

 

Low

 

High

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per common share

 

$

1.49

 

$

1.55

 

$

1.07

 

$

1.13

 

Depreciation and amortization

 

1.20

 

1.20

 

1.11

 

1.11

 

Other depreciation and amortization

 

0.03

 

0.03

 

0.02

 

0.02

 

Taxes associated with real estate disposition

 

0.11

 

0.11

 

—    

 

—    

 

Gain on sales of real estate

 

(0.54)

 

(0.54)

 

(0.43)

 

(0.43)

 

Joint venture FFO adjustments

 

0.06

 

0.06

 

0.11

 

0.11

 

Diluted FFO per common share

 

$

2.35

 

$

2.41

 

$

1.88

 

$

1.94

 

Transaction-related items and other

 

0.21

 

0.21

 

0.01

 

0.01

 

Loss on extinguishment of debt(2)

 

0.10

 

0.10

 

—    

 

—    

 

Severance-related charges(3)

 

0.03

 

0.03

 

—    

 

—    

 

Diluted FFO as adjusted per common share

 

$

2.69

 

$

2.75

 

$

1.89

 

$

1.95

 

 

 

Other Supplemental Information(1)

 

(Unaudited)

 

 

 

Full Year 2016

 

Full Year 2017

 

 

 

Low

 

High

 

Low

 

High

 

 

 

 

 

 

 

 

 

 

 

Amortization of net market lease intangibles and deferred revenues

 

$

(0.01)

 

$

(0.01)

 

$

—  

 

$

—  

 

Amortization of deferred compensation

 

 

0.03

 

 

0.03

 

 

0.04

 

 

0.04

 

Amortization of deferred financing costs

 

 

0.04

 

 

0.04

 

 

0.03

 

 

0.03

 

Straight-line rents

 

 

(0.04)

 

 

(0.04)

 

 

(0.03)

 

 

(0.03)

 

Other depreciation and amortization

 

 

(0.03)

 

 

(0.03)

 

 

(0.02)

 

 

(0.02)

 

Leasing costs and tenant and capital improvements

 

 

(0.19)

 

 

(0.19)

 

 

(0.20)

 

 

(0.20)

 

Lease restructure payments

 

 

0.04

 

 

0.04

 

 

0.01

 

 

0.01

 

Joint venture adjustments – CCRC entrance fees

 

 

0.07

 

 

0.07

 

 

0.07

 

 

0.07

 

Joint venture and other FAD adjustments

 

 

(0.05)

 

 

(0.05)

 

 

(0.09)

 

 

(0.09)

 

 

 

 

(1)

The foregoing projections reflect management’s view of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, development items and the earnings impact of the events referenced in this release. These projections do not reflect unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or existing and future litigation matters including the possibility of larger than expected litigation costs and related developments. Our actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of the date of this press release. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.

 

 

(2)

Prepayment costs associated with early retirement or payment of debt subsequent to the spin and RIDEA II transactions.

 

 

(3)

Severance-related charges primarily relate to the departure of our former President and Chief Executive Officer.

 

Page 13 of 16



 

HCP, Inc.

 

Projected SPP Cash NOI and NOI(1)

 

Dollars in thousands

(Unaudited)

 

For the projected full year 2016 (low):

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

QCP

 

Total

 

NOI(2)

 

$

416,800

 

$

236,700

 

$

289,700

 

$

272,000

 

$

123,700

 

$

402,600

 

$

1,741,500

 

Non-SPP NOI

 

(22,700

)

(126,200

)

(38,600

)

(35,150

)

(27,850

)

(402,600

)

(653,100

)

SPP NOI

 

394,100

 

110,500

 

251,100

 

236,850

 

95,850

 

 

1,088,400

 

Non-cash adjustments to SPP NOI(3)

 

(11,200

)

 

1,500

 

(250

)

(900

)

 

(10,850

)

SPP cash (adjusted) NOI

 

$

382,900

 

$

110,500

 

$

252,600

 

$

236,600

 

$

94,950

 

$

 

 

1,077,550

 

Addback adjustments(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

663,950

 

Other income and expenses(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

253,000

 

Costs and expenses(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,286,700

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

$

707,800

 

 

For the projected full year 2016 (high):

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

QCP

 

Total

 

NOI(2)

 

$

421,100

 

$

238,500

 

$

292,500

 

$

274,600

 

$

124,900

 

$

408,500

 

$

1,760,100

 

Non-SPP NOI

 

(23,000

)

(126,950

)

(39,000

)

(35,450

)

(28,100

)

(408,500

)

(661,000

)

SPP NOI

 

398,100

 

111,550

 

253,500

 

239,150

 

96,800

 

 

1,099,100

 

Non-cash adjustments to SPP NOI(3)

 

(11,400

)

 

1,500

 

(250

)

(900

)

 

(11,050

)

SPP cash (adjusted) NOI

 

$

386,700

 

$

111,550

 

$

255,000

 

$

238,900

 

$

95,900

 

$

 

 

1,088,050

 

Addback adjustments(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

672,050

 

Other income and expenses(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

257,200

 

Costs and expenses(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,282,500

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

$

734,800

 

 

For the year ended December 31, 2015:

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

QCP

 

Total

 

NOI(2)

 

$

424,841

 

$

178,706

 

$

278,261

 

$

254,555

 

$

119,474

 

$

598,254

 

$

1,854,091

 

Non-SPP NOI

 

(31,890

)

(72,191

)

(36,106

)

(20,774

)

(24,941

)

(598,254

)

(784,156

)

SPP NOI

 

392,951

 

106,515

 

242,155

 

233,781

 

94,533

 

 

1,069,935

 

Non-cash adjustments to SPP NOI(3)

 

(11,929

)

 

(6,630

)

(2,465

)

(291

)

 

(21,315

)

SPP cash (adjusted) NOI

 

$

381,022

 

$

106,515

 

$

235,525

 

$

231,316

 

$

94,242

 

$

 

 

1,048,620

 

Addback adjustments(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

805,471

 

Other income and expenses(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

162,951

 

Costs and expenses(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,113,712

)

Impairments, net

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,403,853

)

Impairment of investments in unconsolidated joint ventures

 

 

 

 

 

 

 

(45,895

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

$

(546,418

)

 

 Projected SPP NOI change for the full year 2016:

 

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

Total

 

Low

 

 

0.3%

 

3.75%

 

3.7%

 

1.3%

 

1.4%

 

1.7%

 

High

 

 

1.3%

 

4.75%

 

4.7%

 

2.3%

 

2.4%

 

2.7%

 

 

 Projected SPP cash (adjusted) NOI change for the full year 2016:

 

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

Total

 

Low

 

 

0.5%

 

3.75%

 

7.25%

 

2.3%

 

0.75%

 

2.75%

 

High

 

 

1.5%

 

4.75%

 

8.25%

 

3.3%

 

1.75%

 

3.75%

 

 

Page 14 of 16



 

HCP, Inc.

 

Projected SPP Cash NOI and NOI(1)

 

Dollars in thousands

(Unaudited)

 

 For the projected full year 2017 (low):

 

 

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

Total

 

NOI(2)

 

 

 

$

310,600

 

$

240,500

 

$

268,500

 

$

281,400

 

$

131,700

 

$

1,232,700

 

Non-SPP NOI

 

 

 

(18,200

)

(50,600

)

(37,300

)

(25,300

)

(20,450

)

(151,850

)

SPP NOI

 

 

 

292,400

 

189,900

 

231,200

 

256,100

 

111,250

 

1,080,850

 

Non-cash adjustments to SPP NOI(3)

 

 

 

650

 

 

6,200

 

(700

)

(4,450

)

1,700

 

SPP cash (adjusted) NOI

 

 

 

$

293,050

 

$

189,900

 

$

237,400

 

$

255,400

 

$

106,800

 

1,082,550

 

Addback adjustments(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

150,150

 

Other income and expenses(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

220,500

 

Costs and expenses(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

(933,300

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

$

519,900

 

 

 For the projected full year 2017 (high):

 

 

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

Total

 

NOI(2)

 

 

 

$

314,800

 

$

242,900

 

$

271,400

 

$

284,100

 

$

132,900

 

$

1,246,100

 

Non-SPP NOI

 

 

 

(19,550

)

(51,200

)

(37,900

)

(25,400

)

(20,550

)

(154,600

)

SPP NOI

 

 

 

295,250

 

191,700

 

233,500

 

258,700

 

112,350

 

1,091,500

 

Non-cash adjustments to SPP NOI(3)

 

 

 

650

 

 

6,200

 

(800

)

(4,500

)

1,550

 

SPP cash (adjusted) NOI

 

 

 

$

295,900

 

$

191,700

 

$

239,700

 

$

257,900

 

$

107,850

 

1,093,050

 

Addback adjustments(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

153,050

 

Other income and expenses(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

227,500

 

Costs and expenses(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

(926,300

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

$

547,300

 

 

 For the projected mid-point full year 2016:

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

QCP

 

Total

 

NOI(2)

 

$

418,950

 

$

237,600

 

$

291,100

 

$

273,300

 

$

124,300

 

$

405,550

 

$

1,750,800

 

Non-SPP NOI

 

(130,050

)

(55,000

)

(57,800

)

(22,700

)

(14,900

)

(405,550

)

(686,000

)

SPP NOI

 

288,900

 

182,600

 

233,300

 

250,600

 

109,400

 

 

1,064,800

 

Non-cash adjustments to SPP NOI(3)

 

(5,100

)

 

100

 

(200

)

(3,400

)

 

(8,600

)

SPP cash (adjusted) NOI

 

$

283,800

 

$

182,600

 

$

233,400

 

$

250,400

 

$

106,000

 

$

 

1,056,200

 

Addback adjustments(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

694,600

 

Other income and expenses(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

255,100

 

Costs and expenses(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,284,600

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

$

721,300

 

 

 Projected SPP NOI change for the full year 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

Total

 

Low

 

 

1.2%

 

4.0%

 

(0.9)%

 

2.2%

 

1.7%

 

1.5%

 

High

 

 

2.2%

 

5.0%

 

0.1%

 

3.2%

 

2.7%

 

2.5%

 

 

 Projected SPP cash (adjusted) NOI change for the full year 2017:

 

 

 

 

Senior Housing
Triple-net

 

SHOP

 

Life Science

 

Medical
Office

 

Other

 

Total

 

Low

 

 

3.25%

 

4.0%

 

1.7%

 

2.0%

 

0.75%

 

2.5%

 

High

 

 

4.25%

 

5.0%

 

2.7%

 

3.0%

 

1.75%

 

3.5%

 

 

Page 15 of 16



 


(1)

The foregoing projections reflect management’s view of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, development items and the earnings impact of the events referenced in this release. These projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or existing and future litigation matters including the possibility of larger than expected litigation costs and related developments. Our actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of the date of this press release. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.

 

 

(2)

Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses, including our share of unconsolidated joint ventures.

 

 

(3)

Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net and lease termination fees.

 

 

(4)

Represents non-SPP NOI and non-cash adjustments to SPP NOI.

 

 

(5)

Represents interest income, gain on sales of real estate, other income, net, income taxes and equity income (loss) from unconsolidated joint ventures, excluding NOI.

 

 

(6)

Represents interest expense, depreciation and amortization, general and administrative expenses, and acquisition and pursuit costs.

 

Page 16 of 16